Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.79 +2.1%	$0.71	$0.51 ▼ $1.38	$75.63M	0.28	251,887 shs	97,435 shs
HPPI HedgePath Pharmaceuticals	$0.06	$0.05	$0.04 ▼ $0.32	$32.16M	-1.16	19,283 shs	6,000 shs
IVVD Invivyd	$0.52 -1.5%	$0.73	$0.35 ▼ $2.74	$62.49M	0.51	1.10 million shs	1.59 million shs
JMAC Maxpro Capital Acquisition	$6.04 -0.1%	$6.04	$7.50 ▼ $19.22	$145.16M	0.01	74,040 shs	13,089 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	-3.36%	+4.84%	+11.78%	-39.09%
HPPI HedgePath Pharmaceuticals	+12.32%	+44.75%	+5.85%	-1.70%	-20.66%
IVVD Invivyd	0.00%	-26.45%	-35.79%	-30.51%	-40.76%
JMAC Maxpro Capital Acquisition	-0.09%	+6.61%	+1.25%	-14.62%	+4,663.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.0191 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.8	1.3
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	3.9985 of 5 stars	3.6	5.0	0.0	0.0	2.9	4.2	0.6
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.38	202.24% Upside
HPPI HedgePath Pharmaceuticals	0.00	N/A	N/A	N/A
IVVD Invivyd	3.25	Buy	$3.85	640.24% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HPPI, IVVD, ASRT, and JMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $3.00
8/12/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.61	$0.05 per share	16.01	$0.97 per share	0.81
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	($0.01) per share	N/A
IVVD Invivyd	$46.21M	1.35	N/A	N/A	$0.36 per share	1.44
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.45	N/A	26.19	N/A	-36.97%	-38.19%	-15.45%	11/10/2025 (Estimated)
HPPI HedgePath Pharmaceuticals	-$4.55M	N/A	0.00	∞	N/A	N/A	N/A	-246.03%	N/A
IVVD Invivyd	-$169.93M	-$0.92	N/A	4.73	N/A	-238.33%	-177.89%	-90.96%	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest HPPI, IVVD, ASRT, and JMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	IVVD Invivyd	-$0.04	-$0.12	-$0.08	-$0.12	$23.16 million	$11.79 million
8/11/2025	Q2 2025	ASRT Assertio	-$0.10	-$0.17	-$0.07	-$0.17	$27.86 million	$29.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.42	1.59	1.34
HPPI HedgePath Pharmaceuticals	N/A	6.76	6.76
IVVD Invivyd	N/A	1.33	1.53
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
HPPI HedgePath Pharmaceuticals	N/A
IVVD Invivyd	70.36%
JMAC Maxpro Capital Acquisition	73.18%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
HPPI HedgePath Pharmaceuticals	4.80%
IVVD Invivyd	25.40%
JMAC Maxpro Capital Acquisition	19.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	96.24 million	92.39 million	Optionable
HPPI HedgePath Pharmaceuticals	1	370.45 million	N/A	Not Optionable
IVVD Invivyd	100	120.14 million	89.63 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable

HPPI, IVVD, ASRT, and JMAC Headlines

Recent News About These Companies

Maxpro Capital Acquisition (NASDAQ:JMAC) Trading Up 1.2% - Time to Buy?

August 3, 2025 | marketbeat.com

Denali Capital Acquisition Corp Ordinary Shares - Class A

May 23, 2024 | morningstar.comM

Denali Capital Acquisition Corp Ordinary Shares - Class A DECA Stock Quote

July 21, 2023 | morningstar.comM

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

June 6, 2023 | finance.yahoo.com

Maxpro Capital Acquisition Corp

April 5, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HPPI, IVVD, ASRT, and JMAC Company Descriptions

Assertio NASDAQ:ASRT

$0.79 +0.02 (+2.05%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.78 0.00 (-0.61%)

As of 08/22/2025 07:51 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

HedgePath Pharmaceuticals OTCMKTS:HPPI

$0.06 0.00 (0.00%)

As of 08/22/2025

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Invivyd NASDAQ:IVVD

$0.52 -0.01 (-1.48%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.52 +0.00 (+0.75%)

As of 08/22/2025 07:55 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Maxpro Capital Acquisition NASDAQ:JMAC

$6.04 -0.01 (-0.09%)

As of 08/22/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time